Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4

A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232–255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz et al. (J. Virol. 1991, 65, 3106–3113). Pretreatment of MA-104 cells with...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 16; no. 9; pp. 916 - 920
Main Authors Ijaz, M.K., Nur-E-Kamal, M.S.A., Dar, F.K., Uduman, S., Redmond, M.J., Attah-Poku, S.K., Dent, D., Babiuk, L.A.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 01.05.1998
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232–255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz et al. (J. Virol. 1991, 65, 3106–3113). Pretreatment of MA-104 cells with the VP4-peptide before infection with rotavirus prevented both the attachment of 35S-labelled virus and plaque formation in vitro. In vivo studies using a murine rotavirus model demonstrated that intragastric administration of VP4-peptide protected subjects from challenge with virulent rotavirus. These results clearly indicate the importance of this epitope in virus-cell interactions and their potential as a rotavirus vaccine candidate.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(97)00298-3